FERRING PHARMACEUTICALS TO ACQUIRE MARKETING RIGHTS FOR DDAVP® (DESMOPRESSIN) PRODUCT PORTFOLIO FROM SANOFI

PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is the original developer of the drug desmopressin and has a long-standing history in peptide-based specialty care.

"The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need," said Aaron Graff, President & COO, Ferring Pharmaceuticals Inc. "As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately."

DDAVP is available in the following formulations: DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube and DDAVP® Injection.

About DDAVP®
Ferring has a long-standing interest in the area of endocrinology and pediatric urology, which began with the development of desmopressin (desmopressin acetate) in the mid-1970s.

All desmopressin formulations (DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube, and DDAVP® Injection) are approved by the U.S. Food and Drug Administration (FDA).

You are encouraged to report side effects of prescription drugs. Contact Ferring at 1-888-FERRING (1-888-337-7464) or call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com.

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.